Tranexamic acid in pediatric hemorrhagic trauma

Area of Science:

• Pediatric Trauma Care
• Emergency Medicine
• Hematology

Background:

• Tranexamic acid (TXA) is proven effective in adults when administered within 3 hours of injury.
• Evidence for TXA in pediatric trauma is limited to retrospective studies and observational trials.
• Existing studies suggest potential mortality benefits in pediatric trauma patients.

Purpose of the Study:

• To evaluate the efficacy of tranexamic acid (TXA) in injured children.
• To determine optimal timing, dosage, and patient selection for TXA in pediatric trauma.
• To investigate trauma-induced coagulopathy and fibrinolytic phenotypes in children.

Main Methods:

• Review of existing literature on TXA use in pediatric trauma.
• Identification of the need for randomized controlled trials (RCTs).
• Exploration of viscohemostatic assays for identifying fibrinolytic phenotypes.

Main Results:

• Limited but suggestive evidence indicates TXA may improve mortality in injured children.
• Current data highlights significant gaps in understanding TXA's role in pediatric trauma.
• Three distinct fibrinolytic phenotypes (hyperfibrinolysis, physiologic fibrinolysis, fibrinolytic shutdown) have been identified in trauma patients.

Conclusions:

• Randomized controlled trials are crucial to establish TXA's efficacy and safety in pediatric trauma.
• Further research is needed to understand trauma-induced coagulopathy and fibrinolysis in children.
• The utility of viscohemostatic assays in guiding TXA therapy for children requires investigation.